NRx Pharmaceuticals Inc (NRXPW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NRx Pharmaceuticals Inc (NRXPW) has a cash flow conversion efficiency ratio of 0.311x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.29 Million) by net assets ($-13.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NRXPW net asset quality score to measure how much of total assets are equity-financed.
NRx Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how NRx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NRXPW cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
NRx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NRx Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Us1 Critical Minerals Limited
AU:USC
|
-1.463x |
|
PetroFrontier Corp
V:PFC
|
-0.745x |
|
Ethernity Networks Ltd
LSE:ENET
|
-1.768x |
|
VIFRANA
RO:BIOW
|
N/A |
|
Adheris Health Limited
AU:AHE
|
-5.131x |
|
CuriosityStream Inc
NASDAQ:CURIW
|
0.093x |
|
Versus Systems Inc
NASDAQ:VSSYW
|
0.007x |
|
Tarrina Resources Limited
AU:TR8
|
0.092x |
Annual Cash Flow Conversion Efficiency for NRx Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of NRx Pharmaceuticals Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see how much is NRx Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-15.94 Million | $-14.11 Million | 0.885x | +93.32% |
| 2024-12-31 | $-23.22 Million | $-10.64 Million | 0.458x | -75.19% |
| 2023-12-31 | $-11.73 Million | $-21.66 Million | 1.846x | +134.40% |
| 2022-12-31 | $7.41 Million | $-39.76 Million | -5.366x | -196.10% |
| 2021-12-31 | $20.81 Million | $-37.70 Million | -1.812x | -3601.91% |
| 2020-12-31 | $-43.77 Million | $-2.27 Million | 0.052x | +292.57% |
| 2019-12-31 | $29.50 Million | $-792.73K | -0.027x | -294.90% |
| 2018-12-31 | $69.54 Million | $-473.19K | -0.007x | -248.09% |
| 2017-12-31 | $69.47 Million | $-135.81K | -0.002x | -- |
About NRx Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone… Read more